Company: Pinteon Therapeutics Inc.
Headquarters: Cambridge, Massachusetts, USA
Founded: 2016 [1]
Ticker: Private
CEO: Martin H. Brown (Founder & CEO)
Pinteon Therapeutics is a biotechnology company focused on developing novel therapeutics for neurodegenerative by targeting tau pathology. The company's innovative approach focuses on pathological tau oligomers, toxic protein species that drive the progression of Alzheimer's disease (AD) and other tauopathies including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia (FTD). [2][3]
Pinteon's differentiated strategy distinguishes it from other tau-targeting programs by specifically targeting the "tau streamer" - extracellular tau oligomers that propagate between neurons in a prion-like manner. This targeted approach aims to provide superior efficacy compared to earlier tau antibodies that targeted multiple forms of tau with less specificity. [1:1]
The company has raised significant funding to advance its pipeline, with investors including Moment Bioscience and other biotech-focused venture capital firms. Pinteon operates from its headquarters in the Cambridge biotech hub, positioning it within the rich ecosystem of neuroscience research institutions including Harvard and MIT. [3:1]
Tau is a microtubule-associated protein encoded by the MAPT gene located on chromosome 17q21. In the healthy brain, tau functions to stabilize microtubules, which are essential for axonal transport and neuronal connectivity. The protein contains multiple isoforms generated by alternative splicing, ranging from 352 to 441 amino acids in length. [4]
In Alzheimer's disease and related tauopathies, tau undergoes several pathological modifications:
Recent research has established that tau oligomers represent the most toxic form of aggregated tau. Unlike monomeric tau (which has physiological functions) or insoluble fibrils (which may be relatively inert), oligomers are: [6]
The "tau streamer" concept, central to Pinteon's approach, specifically refers to extracellular tau oligomers that are released from neurons and can propagate pathology to connected brain regions. [7]
Tau pathology spreads through several : [8]
This propagation pattern explains the characteristic staging of tau pathology in AD brains, beginning in the entorhinal cortex and spreading to the hippocampus and cortical regions in a pattern that correlates with cognitive decline. [9]
PNT001 is a monoclonal antibody specifically designed to bind to pathological tau oligomers with high affinity and selectivity. Unlike earlier tau-directed antibodies that targeted monomeric tau or insoluble tangles, PNT001 is engineered to recognize the conformations present in toxic oligomeric species. [2:1][1:2]
Mechanism of Action:
PNT001 was developed using advanced antibody engineering techniques: [2:2]
| Company | Drug | Target Epitope | Target Species | Development Stage |
|---|---|---|---|---|
| Pinteon | PNT001 | Conformational oligomer | Oligomers | Phase 1 |
| Biogen/Eisai | Gosuranemab | N-terminal | Total tau | Phase 3 |
| Roche | Semorinemab | Mid-domain | Total tau | Phase 2 |
| AbbVie/AC Immune | Multiple | Total tau | Phase 1 | |
| Lilly | Semorinemab | Mid-domain | Total tau | Phase 2 |
| Janssen | N-terminal | Total tau | Phase 1 |
This comparison highlights Pinteon's unique focus on oligomeric tau rather than total tau. [10]
PNT001 has advanced through Phase 1 clinical trials, evaluating safety and pharmacokinetics in healthy volunteers and patients with Alzheimer's disease and chronic traumatic encephalopathy (CTE). [2:3][1:3]
Phase 1 Trial Design:
Key Biomarkers Being Evaluated:
Following successful Phase 1 completion, Pinteon plans to advance PNT001 into: [2:4]
| Drug | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| PNT001 | Tau oligomer antibody | Alzheimer's disease Disease | Phase 1 | Completed |
| PNT001 | Tau oligomer antibody | CTE | Phase 1 | Completed |
| PNT002 | Next-gen tau oligomer antibody | Tauopathies | Preclinical | Research |
Pinteon operates in the tau immunotherapy space alongside several major pharmaceutical companies and biotech firms: [10:1]
Pinteon's differentiated focus on tau oligomers rather than total tau or phospho-tau represents a novel approach that may offer several advantages: [7:1]
The tau therapy market represents a significant opportunity: [11]
Beyond AD, tau-targeted therapies address multiple indications:
Key factors driving investment in tau therapeutics include:
The company benefits from an advisory board including leading tauopathy researchers and neuroscientists from academic institutions. Key advisors include: [2:5]
Pinteon has raised funding from venture capital investors focused on neuroscience and neurodegeneration: [3:2]
Investors include Moment Bioscience, TA Group Holdings, and other biotechnology-focused venture capital firms. [3:3]
Pinteon has built a strong intellectual property portfolio covering: [2:6]
Key scientific publications supporting Pinteon's approach include: [6:1][7:2][8:1]
Pinteon collaborates with leading academic institutions for tau research:
Tau Oligomer Targeting - Chen et al. 2023. 2023. ↩︎ ↩︎ ↩︎ ↩︎
Pinteon Therapeutics Corporate Presentation. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Tau Hyperphosphorylation in Alzheimer's - Noble et al. 2022. 2022. ↩︎
Tau Oligomers as Toxic Species - Foley et al. 2021. 2021. ↩︎ ↩︎
Tau Antibody Landscape 2024. 2024. ↩︎ ↩︎